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Dietary DHA reduces downstream endocannabinoid and
inflammatory gene expression and epididymal fat mass while
improving aspects of glucose use in muscle in C57BL/6J mice
J Kim1, ME Carlson1,2, GA Kuchel1, JW Newman3,4,5 and BA Watkins1,4
OBJECTIVES: Endocannabinoid system (ECS) overactivation is associated with increased adiposity and likely contributes to type 2
diabetes risk. Elevated tissue cannabinoid receptor 1 (CB1) and circulating endocannabinoids (ECs) derived from the n-6
polyunsaturated acid (PUFA) arachidonic acid (AA) occur in obese and diabetic patients. Here we investigate whether the n-3 PUFA
docosahexaenoic acid (DHA) in the diet can reduce ECS overactivation (that is, action of ligands, receptors and enzymes of EC
synthesis and degradation) to influence glycemic control. This study targets the ECS tonal regulation of circulating glucose uptake
by skeletal muscle as its primary end point.
DESIGN: Male C57BL/6J mice were fed a semipurified diet containing DHA or the control lipid. Serum, skeletal muscle, epididymal
fat pads and liver were collected after 62 and 118 days of feeding. Metabolites, genes and gene products associated with the ECS,
glucose uptake and metabolism and inflammatory status were measured.
RESULTS: Dietary DHA enrichment reduced epididymal fat pad mass and increased ECS-related genes, whereas it reduced
downstream ECS activation markers, indicating that ECS activation was diminished. The mRNA of glucose-related genes and
proteins elevated in mice fed the DHA diet with increases in DHA-derived and reductions in AA-derived EC and EC-like compounds.
In addition, DHA feeding reduced plasma levels of various inflammatory cytokines, 5-lipoxygenase-dependent inflammatory
mediators and the vasoconstrictive 20-HETE.
CONCLUSIONS: This study provides evidence that DHA feeding altered ECS gene expression to reduce CB1 activation and reduce
fat accretion. Furthermore, the DHA diet led to higher expression of genes associated with glucose use by muscle in mice, and
reduced those associated with systemic inflammatory status.
International Journal of Obesity (2016) 40, 129–137; doi:10.1038/ijo.2015.135
INTRODUCTION
Stimulation of the endocannabinoid system (ECS) has been known
for some time to influence several physiological activities,
including hunger, pain modulation, mood and inflammation, with
the primary function appearing to affect energy homeostasis that
is evident in the shift toward energy storage upon ECS
activation.1–3 The receptors of the ECS, cannabinoid receptors 1
and 2 (CB1 and CB2), belong to the Gi/o protein-coupled receptor
superfamily that can be activated by cannabinoid agonists or
inhibited by antagonists with varying outcomes.4 Signal transduc-
tion following cannabinoid receptor ligand binding is generally
characterized by marked inhibition of adenylyl cyclase.5–7
The ECS role in energy homeostasis is supported by multiple
studies. Models using either pharmacological blockade of CB1- or
CB1-null mice have shown reduced food intake.8,9 However, lower
energy intake did not account for the total body weight
reduction.10,11 In both obese subjects and leptin-deficient mice,
an attenuated glucose uptake and fatty acid oxidation
were reversed by CB1 antagonism.12,13 Anandamide (AEA) and
2-arachidonoylglycerol (2-AG) are the two most frequently
investigated endogenous ECS ligands or endocannabinoids
(ECs). Levels of the two are elevated in obese compared with lean
individuals.14,15 Studies in animal models as well as in humans
report that in conditions of obesity and hyperglycemia the ECS is
in an overactivated state with ligands, receptors and enzymes of
EC synthesis and degradation being upregulated.14–16
CB1 tissue expression and activity have been linked to glucose
use and fatty acid oxidation in peripheral tissues, and intricately
involved in obesity and excessive food intake.17 Both cannabinoid
receptors are expressed in humans and rodents.12 Mice fed high-
fat diets or subjected to diet-induced obesity overexpress CB1 in
skeletal muscle,10,12 a responsive tissue to ECS manipulation.13 For
instance, leptin-deficient obese mice treated with the CB1
antagonist SR141716 for 7 days resulted in the induction of
GLUT1-dependent glucose uptake in isolated soleus muscles.13
After SR141716 treatment, obese mice with elevated soleus
muscle CB1 levels had corrected hyperglycemia, improved insulin
resistance and reduced plasma insulin levels.11 SR141716 expo-
sure increased 2-deoxyglucose uptake by the L6 skeletal muscle
cell line.18 Skeletal muscle from human donors cultured with
media previously used to culture adipocytes (that is, conditioned
media) impaired insulin-stimulated Akt phosphorylation and
reduced cellular glucose uptake.19 The adipocyte-conditioned
media were found to contain AEA, 2-AG and several other ECs.
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Pretreatment of skeletal muscle cells with CB1 antagonists
abolished the reduction of insulin-stimulated glucose uptake.
Similarly, our group has shown higher levels of non-insulin-
stimulated glucose uptake with the CB1 antagonist NESS0327 in
proliferating and differentiated C2C12 myoblasts.20 Treatment
with the docosahexaenoic acid (DHA)-derived EC-like compound,
docosahexaenoyl ethanolamide (DHEA), also elevated glucose
uptake. Collectively, these studies indicate that the ECS may
directly modulate nutrient metabolism in skeletal muscle. Despite
these advances, the molecular mechanisms underlying the actions
of CB1 in skeletal muscle remain to be elucidated along with how
other ECs as well as EC-like compounds derived from DHA
influence receptor level and gene expression in muscle in vivo.
A dysregulated ECS is depicted in both the obese and insulin-
resistant states with specific consequences on systemic glucose
and fatty acid metabolism. Antagonizing CB1 is a potential target
to ameliorate and correct conditions of hyperglycemia. One
approach to study the ECS is to measure mRNA for ECS receptors
and enzymes for the synthesis and degradation of EC and EC-like
compounds in vivo. The mRNA levels of CB1 and enzymes for the
synthesis and degradation of AEA and 2-AG were found to be
increased in abdominal subcutaneous adipose tissue of obese
compared with lean subjects.21 In contrast, the ECS is stimulated
by exercise, leading to elevated plasma AEA and reductions in
adipose CB1 expression.22,23 These findings suggest that fat
catabolism in adipose may result from activation of the ECS, and
perhaps mobilization of fatty acids in muscle under these
conditions may provide arachidonate for the synthesis of AEA
and 2-AG. The arachidonate-derived EC support feeding and in
excess contribute to detrimental consequences on energy home-
ostasis when their levels are elevated. The docosahexaenoate-
derived EC-like compounds may offset the effects of arachidonate
and AEA on glucose metabolism in vivo based on our recent
findings demonstrating improvements in glucose uptake in C2C12
myoblasts.20 The n-3 PUFA have also demonstrated the ability to
lower AEA and 2-AG24 and inflammatory molecules.25 This in turn
could alter the ECS tone (action of ligands, receptors and the
synthesis and degradation enzymes of the ECS) depending on the
relative potency of the resulting EC and EC-like ligand availability
within tissues.
The aim of the study was to determine how dietary DHA affects
the ECS and glucose utilization in mice. The specific research
hypothesis is that dietary DHA administered in a semipurified diet
fed to C57BL/6J mice will restore EC tone to improve muscle
glucose use and decrease fat accretion. Measurements of growth,
body composition and tissue fatty acids along with ECs and an
extensive array of inflammatory mediators and oxidative stress
markers were performed to allow for the assessment of
interactions between these fundamentally linked systems. Tissues
were collected for quantitative real-time PCR and western blot
analysis of EC enzymes related to glucose homeostasis to test our
hypothesis.
MATERIALS AND METHODS
Animals, diets and experimental design
A total of 80 21-day-old male C57BL/6J mice (The Jackson Laboratory, Bar
Harbor, ME, USA) were fed a modified AIN-93G diet (containing 11.04% fat)
(Dyets, Bethlehem, PA, USA) for 62 or 118 days.26 Mice were assigned to
either the control diet containing safflower oil or the DHA-enriched diet.
Both diets were isocaloric and isonitrogenous, and thus the two diets
varied only in their lipid source (Supplementary Table 1). Total fatty acid
analysis of the diets showed that the control diet contained 0.2% n-3
polyunsaturated acid (PUFA) of total fatty acids and had a ratio of n-6/n-3
PUFA of 298, whereas the DHA diet contained 5.9% DHA of total fatty acids
and had a ratio of n-6/n-3 of 10.5. The amount of DHA administered in the
DHA diet was ∼ 1100mg kg− 1 per day that was determined by metabolic
body size with an average daily food intake of 5 g per day per mouse for
both groups.
Body weights were recorded once a week for the duration of the study,
and food intake was recorded once each week. After 62 and 118 days of
feeding, 9 mice from each group were weighed and anesthetized with
isoflurane after fasting for 8 h. Blood was then collected for sera prep
followed by cervical dislocation. The mice were then subjected to dual-
energy X-ray absorptiometry (DXA) to measure lean and fat mass (pDXA
Sabre; Norland Medical Systems, Inc., Fort Atkinson, WI, USA). Following the
DXA scan, quadriceps, gastrocnemius, anterior tibialis, epididymal fat pads
and liver were harvested, weighed and immediately frozen in liquid
nitrogen. Animal care protocols were approved by and met all University of
Connecticut Health Center Animal Care Committee procedures and
guidelines.
Dual-energy X-ray absorptiometry
Mouse lean mass (muscle mass density) and fat mass measurements were
performed by DXA following the manufacturer’s calibration protocols.26
Calibration was performed with a defined standard containing hydro-
xyapatite crystals embedded in Lucite (corresponding to bone mineral
density = 0.0594 g cm− 2, percent fat = 12.4%). Measurements were per-
formed at a speed of 7 mm s− 1 and a resolution of 0.5 × 0.5 mm.
Fatty acid methyl ester analysis
Fatty acid composition of serum, anterior tibialis, quadriceps, epididymal
fat pad and liver was measured by gas chromatography and flame
ionization detection of fatty acid methyl esters. Tissue lipids were extracted
with chloroform/methanol (2:1, vol/vol) and sonication. Extracted lipids
were hydrolyzed with 0.5 N methanolic NaOH, and fatty acids were
methylated with 10% (w/w) methanolic boron trifluoride. The solvent was
removed, and the residue was reconstituted in isooctane and analyzed on
a 7890A gas chromatograph equipped with a 30m×0.25mm×0.15 mm
DB-225 column and flame ionization detector (Agilent Technologies,
Palo Alto, CA, USA).27 Sample peaks were identified by comparison with
authentic standards (Nu-Chek-Prep Inc., Elysian, MN, USA). Results of fatty
acid methyl ester analysis values were determined by weight percentage
reports based on the retention times and peak responses of authentic
standards (not detected less than 50 ng per peak).
EC and oxylipin analyses
ECs and oxylipins were measured in 36 serum samples (control and DHA-
diet fed groups collected at day 62 and day 118) using 250 μl of serum as
previously described.28 Briefly, the plasma samples were thawed on ice,
added to solid-phase extraction column cartridges on a vacuum manifold,
spiked with deuterated EC and oxylipin internal standards, up-diluted to
20% MeOH/0.1% acetic acid and gravity loaded onto 60mg Oasis-HLB
solid-phase extraction column (Waters, Inc., Milford, MA, USA) followed by
vacuum. Columns were then wetted with 0.2 ml MeOH and eluted with
1.5 ml ethyl acetate by gravity. Solvent was removed by vacuum, sample
reconstituted in 50 μl MeOH containing the internal standard 1-cyclohexyl-
3-dodecyl-urea (Sigma Aldrich, St Louis, MO, USA) and samples were
filtered and analyzed by ultraperformance liquid chromatography electro-
spray ionization-tandem mass spectrometry by back-to-back (+)-mode/
(− )-mode injections for EC and oxylipin levels, respectively.
29,30
Quantitative real-time PCR
The primers sequences used in this work are shown in Supplementary
Table 2. Additional details of gene expression are outlined in
Supplementary Materials and Methods.
Western blot analysis
Antibodies (α-mouse-CB1, α-mouse-CB2, α-rabbit-GLUT4, α-rabbit-Insulin-
R) were purchased from Abcam (Cambridge, MA, USA) and detected via
chemiluminescence. Additional details of protein expression analysis are
outlined in Supplementary Materials and Methods.
Statistical analysis
All data were analyzed for significance in SAS version 9.3 (SAS Institute Inc.,
Cary, NC, USA). Mean differences were evaluated by Student’s t-test for
gene expression or by Mann–Whitney U-test for EC and oxylipin
concentrations. Significance level was defined as Po0.05. In the case for
gene expression data where significant differences were found, Tukey’s
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multiple comparison test was performed at a probability of α 0.05. Relative
CT amounts for mRNA values were calculated from the standard curve for
each gene that were normalized to GAPDH expression afterwards.
RESULTS
Body weight, food intake and body composition
All mice in either diet group gained weight steadily throughout
the feeding study and no differences were observed
(Supplementary Figure 1). Feed intake on a cage basis showed
no difference in the amount of diet consumed and weight change,
weight gain and feed intake, and feed to gain ratios were not
different between the control and DHA groups.
Whole-body DXA scan for lean mass and fat mass revealed
differences at 118 days of feeding (Supplementary Figure 2). Mice fed
the DHA diet had a higher lean mass (17.59 vs 12.56 g, P=0.0092)
and lower fat mass (14.61 vs 23.79 g, P=0.0049) at the 118 day time
point compared with those fed the control diet. Similarly, mouse
epididymal fat pad mass was higher in the control compared with
the DHA group (left, 1.09 vs 0.66 g, P= .0004; right, 1.12 vs 0.63 g,
P= .0003). Mouse total fat mass determined by DXA was consistent
with the results for epididymal fat pad weights.
Muscle, fat and liver fatty acid composition
Mice fed the DHA semipurified diet had higher n-3 PUFA and
lower arachidonate levels in anterior tibialis, epididymal fat pads
and liver compared with those given the control diet
(Supplementary Tables 3–5). After 62 days of DHA diet feeding,
the anterior tibialis of mice showed higher levels of 16:1t, 20:1n9,
20:5n3, 22:6n3, 24:0 and 24:1n9 compared with mice fed the
control diet (Supplementary Table 3), and a reduced ratio of n-6/n-3
PUFA (DHA=0.950, Control = 10.8; P=0.0001). After 118 days of
feeding, anterior tibialis frommice fed the DHA diet had higher levels
of 14:0, 15:0, 16:0, 17:0, 20:5n3, 22:5n3 and 22:6n3 (Supplementary
Table 3), and again the ratio of n-6/n-3 PUFA was lower in mice fed
the DHA diet compared with the control group (DHA=1.43;
Control = 27.4; Po0.0001). In epididymal fat pads, 62 days of dietary
DHA enrichment increased the levels of 14:0, 17:0, 18:0 and 22:6n3
(Supplementary Table 4) and lowered the ratio of n-6/n-3 PUFA
(DHA=26.8; Control = 135; P=0.0029). After 118 days of feeding,
these fat pads showed elevated 12:0, 14:0, 15:0, 16:1t, 17:0, 20:5n3,
22:5n3 and 22:6n3 with DHA feeding (Supplementary Table 4),
and a similar reduction in the ratio of n-6/n-3 PUFA (DHA= 31.2,
Control = 712; Po0.001). After 62 days of DHA feeding, 15:0, 16:0,
18:2n6, 18:3n3, 20:5n3, 22:6n3, and 24:1n9 were elevated in the
liver (Supplementary Table 5), and the ratio of n-6/n-3 PUFA was
lower in the DHA diet compared with the controls (DHA=3.01,
Control = 54.1; P=0.0047). After 118 days of feeding, liver from the
mice fed the DHA diet had higher levels of 15:0, 17:0, 18:0, 18:2n6,
20:0, 20:5n3, 22:0, 22:5n3 and 22:6n3 (Supplementary Table 5).
Plasma ECs and related compounds
Higher levels of plasma DHEA were found consistently in mice fed
the DHA diet at 62 and 118 days compared with control mice at
both time points (Table 1). Moreover, DHA feeding was
accompanied by lower levels of the arachidonic acid (AA)-derived
AEA, DEA, 1-AG and 2-AG, as well as other EC-like compounds
including 1-OG, 2-OG, SEA, OEA and dihomo GLA-EA at both time
points. These observations in plasma ECs follow the remodeling of
fatty acid composition for anterior tibialis (Supplementary Table 3),
epididymal fat pad (Supplementary Table 4) and liver
(Supplementary Table 5).
ECS-, glucose uptake- and inflammation-related expression
Quadriceps and epididymal fat pad quantitative real-time PCR
mRNA expression of ECS- and glucose metabolism-related genes
revealed several differences. Reported values were normalized to
the housekeeping gene GAPDH and shown in Tables 2 and 3. After
62 days of dietary DHA treatment, mRNA levels for both CB1 and
CB2 in quadriceps were elevated. These changes were also
maintained after 118 days of feeding. Western blot analysis
followed by densitometry confirmed these findings (Figure 1). In
contrast, DHA feeding reduced CB1 and increased CB2 mRNA in
epididymal fat at 62 and 118 days, but protein levels matched
mRNA results only at 62 days. CB1 protein increased whereas CB2
protein decreased after 118 days of DHA feeding.
Table 1. Plasma endocannabinoid levels in mice fed the control and DHA semipurified diet after 62 and 118 days
Metabolite Substrate Day 62 Day 118 Mean testing P-values
Control DHA Control DHA Day 62 Day 118 62 vs118 days
control
62 vs 118 days
DHA
1-OG 18:1n9 322±30 172± 19 514± 61 213± 12 ‡ ‡ ‡ ‡
2-OG 18:1n9 2730± 158 15 820± 184 3900± 420 1880± 91 ‡ ‡ ‡ ‡
1-LG 18:2n6 41.7± 4.3 83.7± 20.1 59.9± 22.5 53.1± 7.1 ‡ 0.4 * †
2-LG 18:2n6 5870± 179 5930± 674 6350± 513 5390± 330 0.8 ‡ ‡ *
1-AG 20:4n6 5.01± 0.89 1.96± 0.35 7.22± 1.71 1.77± 0.16 ‡ ‡ † 0.2
2-AG 20:4n6 156± 12 102± 7 181± 23 82.7± 6.1 ‡ ‡ * ‡
PEA 16:0 23.4± 1.4 26.1± 2.1 32.4± 42 35.4± 2.1 † 0.07 ‡ ‡
SEA 18:0 460± 34 258± 29 838± 73 470± 45 ‡ ‡ ‡ ‡
OEA 18:1n9 312± 47 187± 27 846± 215 347± 67 ‡ ‡ ‡ ‡
LEA 18:2n6 27.0± 2.7 21.3± 2.4 42.5± 3.58 29.0± 2.2 ‡ ‡ ‡ ‡
α-LEA 18:3n3 0.02± 0.00 0.02± 0.01 — — — 1
Dihomo GLA EA 20:3n6 4.03± 0.38 2.27± 0.16 5.45± 0.52 3.38± 0.3 ‡ ‡ ‡ ‡
AEA 20:4n6 3.57± 0.34 1.31± 0.12 5.97± 0.44 1.78± 0.13 ‡ ‡ ‡ ‡
DEA 22:4n6 8.55± 0.82 0.88± 0.11 13.6± 2.08 1.36± 0.3 ‡ ‡ ‡ ‡
DHEA 22:6n3 0.3± 0.03 3.41± 0.32 0.27± 0.02 4.23± 0.31 ‡ ‡ * ‡
Abbreviations: AEA, anandamide; 1-AG, 1-arachidonoylglycerol; 2-AG, 2-arachidonoylglycerol; DEA, docosatetraenoyl ethanolamide; DHA, docosahexaenoic
acid; DHEA, docosahexaenoyl ethanolamide; Dihomo-GLA-EA, dihomo-γ-linolenoyl ethanolamide; LEA, linoleoyl ethanolamide; α-LEA, α-linolenoyl
ethanolamide; 1-LG, 1-linoleoyl ethanolamide; 2-LG, 2-linoleoyl ethanolamide; OEA, oleoyl ethanolamide; 1-OG, 1-oleoyl ethanolamide; 2-OG, 2-oleoyl
ethanolamide; PEA, palmitoyl ethanolamide; SEA, stearoyl ethanolamide. Values are mean± s.d. of nine samples from each group at each time point (values
expressed as nM). Differences between diet groups and between time within the same diet groups were compared by Mann–Whitney U-test. Significant
differences in means: *Po0.05, †Po0.01 and ‡Po0.001.
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Table 2. Comparison of ECS and glucose uptake-related mRNA in mouse quadriceps after 62 and 118 days of feeding AIN 93M semipurified diets
Measurements Day 62 Day 118 Mean testing P-value
Control DHA Control DHA Day 62 Day 118 62 vs118 days control 62 vs 118 days DHA
CB1 1.0± 0.05 2.4± 0.1 1.0± 0.1 2.3± 0.2 ‡ ‡ 1 0.2
CB2 1.0± 0.1 3.3± 0.3 1.0± 0.05 5.2± 0.5 ‡ ‡ 1 ‡
NAPE-PLD 1.0± 0.1 2.1± 0.2 1.0± 0.1 2.7± 0.2 ‡ ‡ 1 ‡
FAAH 1.0± 0.1 1.2± 0.1 1.0± 0.1 1.3± 0.1 ‡ † 1 0.06
DAGL-α 1.0± 0.1 1.4± 0.1 1.0± 0.1 1.8± 0.1 ‡ ‡ 1 ‡
DAGL-β 1.0± 0.1 1.9± 0.1 1.0± 0.1 1.7± 0.1 ‡ ‡ 1 †
Akt-1 1.0± 0.1 1.6± 0.2 1.0± 0.05 1.9± 0.1 ‡ ‡ 1 ‡
Insulin R 1.0± 0.1 1.9± 0.2 1.0± 0.05 4.1± 0.3 ‡ ‡ 1 ‡
IRS-1 1.0± 0.1 1.6± 0.2 1.0± 0.1 2.9± 0.2 ‡ ‡ 1 ‡
GLUT4 1.0± 0.1 2.7± 0.1 1.0± 0.04 4.1± 0.4 ‡ ‡ 0.9 ‡
GLUT1 1.0± 0.1 3.7± 0.3 1.0± 0.1 7.3± 0.4 ‡ ‡ 1 ‡
Myogenin 1.0± 0.03 1.0± 0.1 1.0± 0.04 1.0± 0.03 0.8 0.06 1 0.2
MyoD1 1.0± 0.04 0.9± 0.1 1.0± 0.1 1.0± 0.1 * 0.4 0.9 0.3
IL-6 1.0± 0.1 0.5± 0.04 1.0± 0.1 0.4± 0.03 ‡ ‡ 0.9 †
TNF-α 1.0± 0.1 0.4± 0.03 1.0± 0.1 0.5± 0.1 ‡ ‡ 1 0.09
AMPK α2 1.0± 0.1 1.4± 0.1 1.0± 0.1 1.8± 0.1 ‡ ‡ 1 ‡
Adenylate Cyclase 1.0± 0.1 1.1± 0.1 1.0± 0.1 1.3± 0.1 * ‡ 1 ‡
p42/p44 (MAPK) 1.0± 0.04 0.6± 0.04 1.0± 0.1 0.7± 0.1 ‡ ‡ 1 *
p38 (MAPK) 1.0± 0.1 0.7± 0.02 1.0± 0.04 0.6± 0.1 ‡ ‡ 0.9 *
JNK (MAPK) 1.0± 0.1 0.6± 0.03 1.0± 0.1 0.5± 0.03 ‡ ‡ 0.9 †
Abbreviations: Akt1, RAC-α serine/threonine-protein kinase (protein kinase B); CB1, cannabinoid receptor 1; CB2, cannabinoid receptor 2; DAGLα,
diacylglycerol lipase-α; DAGLβ, diacylglycerol lipase-β; DHA, docosahexaenoic acid; EAC, endocannabinoid system; FAAH, fatty acid amide hydrolase; GLUT4,
glucose transporter type 4; IL-6, interleukin-6; INS-R, insulin receptor; JNK, Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MyoD1, myogenic
differentiation; NAPE-PLD, N-acyl phosphatidylethanolamine phospholipase D; TNF-α, tumor necrosis factor-α. Values are the mean± s.d. (n= 9) of ΔΔCT
calculated from mouse tissue mRNA. Differences between diet groups and between time within the same diet groups were compared by t-test. Mean values of
quantitative real-time PCR (qPCR) data were compared by t-test using SAS software. Significant differences in means: *Po0.05, †Po0.01 and ‡Po0.001.
Table 3. Comparison of ECS and glucose uptake-related mRNA in mouse epididymal fat pad after 62 and 118 days of feeding AIN 93M semipurified
diets
Measurements Day 62 Day 118 Mean testing P-value
Control DHA Control DHA Day 62 Day 118 62 vs118 days control 62 vs 118 days DHA
CB1 1.0± 0.1 0.4± 0.03 1.0± 0.1 0.2± 0.01 ‡ ‡ 0.9 ‡
CB2 1.0± 0.1 1.8± 0.2 1.0± 0.1 1.9± 0.2 ‡ ‡ 0.9 0.5
NAPE-PLD 1.0± 0.1 2.1± 0.2 1.0± 0.1 2.4± 0.2 ‡ ‡ 1 †
FAAH 1.0± 0.1 1.0± 0.1 1.0± 0.1 1.2± 0.1 0.8 † ‡
DAGL-α 1.0± 0.1 0.6± 0.03 1.0± 0.1 0.3± 0.02 ‡ ‡ 0.9 ‡
DAGL-β 1.0± 0.05 0.7± 0.1 1.0± 0.04 0.4± 0.02 ‡ ‡ 1 ‡
Akt-1 1.0± 0.1 0.7± 0.04 1.0± 0.1 0.4± 0.01 ‡ ‡ 1 ‡
Insulin R 1.0± 0.1 0.5± 0.03 1.0± 0.1 0.5± 0.04 ‡ ‡ 1 †
IRS-1 1.0± 0.1 1.5± 0.1 1.0± 0.1 1.8± 0.1 ‡ ‡ 0.9 ‡
GLUT4 1.0± 0.1 0.6± 0.04 1.0± 0.1 0.3± 0.02 ‡ ‡ 1 ‡
GLUT1 1.0± 0.1 1.6± 0.1 1.0± 0.1 2.2± 0.1 ‡ ‡ 1 ‡
Adiponectin 1.0± 0.1 1.9± 0.1 1.0± 0.04 2.8± 0.2 ‡ ‡ 0.9 ‡
IL-6 1.0± 0.1 0.7± 0.04 1.0± 0.1 0.5± 0.02 ‡ ‡ 1 ‡
TNF-α 1.0± 0.05 0.5± 0.04 1.0± 0.1 0.5± 0.03 ‡ ‡ 1 ‡
MCP1 1.0± 0.1 0.7± 0.05 1.0± 0.1 0.6± 0.03 ‡ ‡ 1 ‡
AMPK α2 1.0± 0.1 1.6± 0.1 1.0± 0.1 1.6± 0.1 ‡ ‡ 1 0.4
Adenylate Cyclase 1.0± 0.1 1.1± 0.04 1.0± 0.04 2.1± 0.1 ‡ ‡ 1 ‡
p42/p44 (MAPK) 1.0± 0.1 0.8± 0.1 1.0± 0.1 0.6± 0.1 ‡ ‡ 1 †
p38 (MAPK) 1.0± 0.1 0.5± 0.03 1.0± 0.1 0.5± 0.03 ‡ ‡ 0.9 0.3
JNK (MAPK) 1.0± 0.1 0.6± 0.1 1.0± 0.1 0.4± 0.03 ‡ ‡ 1 ‡
Abbreviations: Akt1, RAC-α serine/threonine-protein kinase (protein kinase B); CB1, cannabinoid receptor 1; CB2, cannabinoid receptor 2; DAGLα,
diacylglycerol lipase-α; DAGLβ, diacylglycerol lipase-β; DHA, docosahexaenoic acid; EAC, endocannabinoid system; FAAH, fatty acid amide hydrolase; GLUT4,
glucose transporter type 4; IL-6, interleukin-6; INS-R, insulin receptor; JNK, Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MyoD1, myogenic
differentiation; NAPE-PLD, N-acyl phosphatidylethanolamine phospholipase D; TNF-α, tumor necrosis factor-α. Values are the mean± s.d. (n= 9) of ΔΔCT
calculated from mouse tissue mRNA. Differences between diet groups and between time within the same diet groups were compared by t-test. Mean values of
quantitative real-time PCR (qPCR) data were compared by t-test using SAS software. Significant differences in means: *Po0.05, †Po0.01 and ‡Po0.001.
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As with the receptor levels, synthesis and degradation gene
expression levels differed between the quadriceps muscle and
adipose samples. The AEA synthesis enzyme, N-acyl phosphatidy-
lethanolamine phospholipase D (NAPE-PLD), and the 2-AG
synthesis enzyme, diacylglycerol lipase (DAGL)-α and DAGL-β,
and fatty acid amide hydrolase (FAAH) enzyme responsible for the
degradation of both ligands were elevated in quadriceps of mice
fed the DHA diet after both 62 and 118 days of DHA diet feeding
(Table 2). However, epididymal fat pads showed higher NAPE-PLD
expression but lower levels of DAGL-α and -β isoforms at both 62
and 118 days of feeding, whereas FAAH was unchanged at
62 days but elevated at 118 days (Table 3).
Cell status markers
Expression of myogenin and MyoD1 indicates myogenesis.31
Only after 62 days, mice fed the DHA diet showed a decrease in
MyoD1 mRNA in quadriceps. The 5’ adenosine monophosphate-
activated protein kinase (AMPK)-α2 mRNA levels were higher
in mice fed the DHA diet at both 62 and 118 days in both
quadriceps and epididymal fat pads compared with the control
mice (Tables 2 and 3).
ECS confirmation (mitogen-activated protein kinase + adenylyl
cyclase)
In order to validate ECS receptor activity, several downstream
events found previously to occur with activation were analyzed.4,32,33
Here we see a higher expression of adenylyl cyclase and a lower
expression of the mitogen-activated protein kinase enzymes, p42/
p44, p38 and Jun N-terminal kinase, in the mice fed the DHA diet
at both 62 and 118 days in quadriceps and epididymal fat pads.
Though only mRNA expression was analyzed here, these findings
in the DHA diet-fed mice demonstrate that the potential for
downstream events of ECS activation are diminished.
Glucose aspects
Quadriceps collected from mice fed the DHA diet had higher
levels of Akt-1, insulin receptor, insulin receptor substrate-1,
GLUT4 and GLUT1 mRNA after 62 and 118 days of feeding
(Table 2). Western blot analysis reflected the higher levels of
GLUT4 and insulin receptor expression (Figure 1). However, in
epididymal fat pads DHA feeding reduced Akt-1, insulin receptor
and GLUT4 mRNA, but increased insulin receptor substrate-1,
GLUT1 and adiponectin mRNA (Table 3).
Inflammation
DHA feeding lead to reductions in both tissue inflammatory
cytokines and plasma pro-inflammatory lipid mediator profiles.
Quadriceps from mice fed the DHA diet had lower levels of
interleukin-6 and tumor necrosis factor-α mRNA after 62 and
118 days of feeding compared with the mice fed the control diet.
Epididymal fat pad mRNA levels of interleukin-6, tumor necrosis
factor-α and monocyte chemotactic protein-1 values were lower in
mice fed the DHA diet after 62 and 118 days of feeding.
Several oxylipins were altered by DHA feeding (Table 4).
Although many n-3 oxylipins were reduced and n-6 oxylipins
increased by DHA feeding, not all detected compounds followed
this behavior. For instance the AA-derived diols (DiHETrEs) and
epoxides (EpETrEs) were reduced whereas the n-3 PUFA-derived
HEPEs, HDoHEs, Di-HETEs, DiHDoPE, EpETEs and EpDoPEs
were increased. In addition, by 118 days all of the measured
5-lipoxygenase-dependent metabolites were reduced including
Lipoxin A4 (fivefold), LTB4 (twofold), 5-HETE (fourfold) and 5-KETE
(sixfold; P= 0.053). Of particular note, metabolites associated with
5-lipoxygenase metabolism including Lipoxin A4, LTB4 and 5-HETE
were reduced, whereas the autooxidation markers 9-HETE, PGF2a
and the measured fatty acid hydroperoxides were unchanged.
DISCUSSION
To date, few studies have directly investigated the interactions of
n-3 fatty acid feeding and changes in the ECS as they relate to fat
accretion and glucose metabolism. Here we specifically examined
how dietary DHA affects the ECS and subsequent metabolic
functions associated with obesity and type 2 diabetes in muscle
and adipose tissues. Upon glucose challenge, skeletal muscle can
account for as much as 95% of whole body glucose uptake.34 We
have found that feeding mice a semipurified diet rich in DHA not
only reduced the n-6/n-3 PUFA ratio in tissues, but also reduced
epididymal fat pad mass and produced broad changes in ECS-
associated gene and protein expression in both skeletal muscle
and adipose tissues. These findings coincide with those in rodents
fed n-6- or n-3-enriched diets in bone26,35,36 and quadriceps.37
As expected, changes in dietary fatty acids significantly altered
tissue fatty acid composition and a number of tissue-specific
processes associated with lipid metabolism. Interestingly, of the
tissues evaluated here, the greatest increase in DHA and decrease
in AA (20:4n6) was found in the anterior tibialis. Such changes in
plasma membrane lipid composition can have direct consequence
on the stability and architecture of membranes that in turn
changes the availability of biosynthetic precursors and various
membrane receptors, including those involved in glucose
homeostasis. As shown in Supplementary Table 5, indices of
stearoyl-coenzyme A desaturase activity (that is, 18:1n9/18:0 and
Figure 1. CB1, CB2, GLUT4 and INSULIN-R expression in mouse
quadriceps and epididymal fat pad after 62 and 118 days of feeding
AIN 93M semipurified diets: western blot comparison between the
treatment (DHA) and control groups. Values are mean± s.d. for
n= 9 measurements. Differences between diet groups and time
were compared by t-test. * represents differences between diet
groups; † indicates significant difference over time within the same
diet group.
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Table 4. Plasma oxylipin levels in mice fed the control and DHA semipurified diet after 62 and 118 days
Metabolites Day 62 Day 118 Mean testing P-value
Control DHA Control DHA Day 62 Day 118 62 vs118 days control 62 vs 118 days DHA
TXB2 14.6± 6.6 12.3± 5.2 52.5± 30.3 14.3± 4.0 0.8 0.2 0.2 0.8
6-keto PGF1a 1.53± 0.64 1.06± 0.59 1.91± 0.82 1.02± 1.00 0.6 0.5 0.7 1
PGE1 0.04± 0.01 0.03± 0.01 0.12± 0.02 0.09± 0.04 0.6 0.4 † 0.2
PGE2 0.52± 0.12 0.35± 0.15 1.18± 0.38 0.51± 0.17 0.4 0.1 0.1 0.5
PGD2 0.66± 0.15 0.43± 0.23 1.53± 0.48 0.68± 0.19 0.4 0.1 0.1 0.4
15-deoxy PGJ2 0.08± 0.01 0.11± 0.01 0.08± 0.01 0.1± 0.01 * 0.2 0.7 0.4
PGF2a 0.36± 0.13 0.29± 0.13 1.14± 0.58 0.25± 0.08 0.7 0.1 0.2 0.8
9,12,13-TriHOME 1.2± 0.13 1.64± 0.49 2.26± 0.89 1.96± 0.69 0.4 0.8 0.2 0.7
9,10-13-TriHOME 2.88± 0.19 4.28± 1.4 5.34± 2.35 4.74± 1.60 0.3 0.8 0.3 0.8
12,13-DiHOME 24.2± 3.5 64.7± 7.8 36.7± 9.6 42.6± 9.2 ‡ 0.6 0.2 0.07
9,10-DiHOME 193± 22 307± 31 264± 73 215± 42 † 0.5 0.3 0.08
15,16-DiHODE 0.31± 0.04 0.48± 0.05 0.94± 0.51 0.39± 0.05 * 0.3 0.2 0.2
12,13-DiHODE 0.03± 0.01 0.05± 0.01 0.09± 0.04 0.03± 0.01 0.2 0.2 0.2 0.3
9,10-DiHODE 0.09± 0.01 0.10± 0.01 0.56± 0.24 0.11± 0.03 0.7 0.09 0.08 0.6
14,15-DiHETrE 2.58± 0.15 1.13± 0.13 3.77± 0.50 1.02± 0.17 ‡ ‡ * 0.6
11,12-DiHETrE 1.13± 0.08 0.48± 0.06 2.02± 0.34 0.49± 0.09 ‡ † * 0.9
8,9-DiHETrE 2.21± 0.11 0.62± 0.03 2.90± 0.39 0.69± 0.09 ‡ ‡ 0.1 0.5
5,6-DiHETrE 1.43± 0.12 0.25± 0.03 1.83± 0.20 0.4± 0.08 ‡ ‡ 0.09 0.08
17,18-DiHETE 1.07± 0.11 24.8± 4.7 1.37± 0.27 35.0± 6.4 † ‡ 0.3 0.2
14,15-DiHETE 0.17± 0.02 3.99± 0.95 0.23± 0.05 4.99± 1.10 † † 0.2 0.5
19,20-DiHDoPE 0.77± 0.04 20.0± 2.2 1.02± 0.23 25.3± 3.7 ‡ ‡ 0.3 0.2
Lipoxin A4 0.36± 0.03 0.21± 0.14 0.81± 0.20 0.16± 0.04 0.3 * * 0.7
LTB4 0.18± 0.05 0.19± 0.12 0.39± 0.08 0.20± 0.04 1 * * 1
6-trans-LTB4 0.23± 0.07 0.28± 0.22 0.57± 0.16 0.19± 0.05 0.8 * 0.07 0.7
5,15-DiHETE 0.03± 0.01 0.03± 0.01 0.05± 0.01 0.02± 0.01 0.9 0.2 0.2 0.9
13-HODE 235± 24 576± 133 513± 120 887± 296 * 0.2 * 0.3
9-HODE 25.8± 2.2 64.3± 18.2 46.3± 12.7 62.4± 16.5 0.06 0.4 0.1 0.9
13-HOTE 0.92± 0.10 1.2± 0.23 1.22± 0.28 1.53± 0.37 0.3 0.5 0.3 0.4
9-HOTE 0.45± 0.03 0.75± 0.15 0.60± 0.13 0.78± 0.17 0.06 0.4 0.3 0.9
15-HETrE 1.52± 0.31 1.06± 0.31 4.21± 0.88 2.65± 0.75 0.3 0.2 * 0.06
20-HETE 1.98± 0.33 0.64± 0.08 3.87± 0.88 0.44± 0.12 † † 0.06 0.2
15-HETE 8.76± 1.93 4.83± 1.84 21.0± 7.0 6.23± 1.66 0.1 0.06 0.1 0.6
12-HETE 699± 187 608± 203 1820± 0 1160± 180 0.7 — — *
11-HETE 1.74± 0.64 1.94± 0.88 4.92± 2.14 1.86± 0.51 0.8 0.2 0.2 0.9
9-HETE 0.24± 0.03 0.44± 0.00 0.48± 0.17 0.81± 0.00 — — 0.2 —
8-HETE 7.56± 1.45 2.77± 0.68 19.1± 3.6 5.96± 1.38 † † * *
5-HETE 10.4± 1.01 2.63± 1.01 11.8± 1.2 2.84± 0.57 ‡ ‡ 0.3 0.8
15-HEPE 0.21± 0.03 1.28± 0.29 0.24± 0.03 3.19± 0.81 † † 0.5 *
12-HEPE 3.45± 1.09 185± 66 11.4± 2.6 685± 216 * * * *
9-HEPE 0.01± 0.00 0.47± 0.09 0.10± 0.09 0.74± 0.18 † † 0.3 0.2
5-HEPE — 0.88± 0.17 0.06± 0.03 1.11± 0.17 — ‡ — 0.3
17-HDoHE 1.48± 0.32 21.2± 5.3 2.9± 0.60 79.9± 21.8 † † * *
14-HDoHE 12.1± 3.3 277± 87 28.0± 8.3 1070± 277 * † 0.09 *
13-KODE 17.5± 2.4 71.3± 30.0 33.8± 12.5 47.3± 13.6 0.09 0.5 0.2 0.5
9-KODE 11.5± 1.1 66.7± 33 20.3± 7.1 34.3± 8.3 0.1 0.2 0.2 0.3
12(13)-Ep-9-KODE 11.1± 1.2 70.8± 41.5 24.0± 10 34.8± 11.3 0.2 0.5 0.2 0.4
5-KETE 1.4± 0.2 0.81± 0.67 2.22± 0.84 0.38± 0.19 0.4 0.05 0.3 0.5
12(13)-EpOME 102± 6.2 188± 18 171± 24 150± 19 ‡ 0.5 * 0.1
9(10)-EpOME 78.7± 4.7 172± 17 125± 23 133± 21 ‡ 0.8 0.07 0.1
15(16)-EpODE 0.86± 0.11 1.79± 0.48 2.0± 0.60 1.17± 0.12 0.08 0.2 0.08 0.2
12(13)-EpODE 0.12± 0.01 0.24± 0.03 0.25± 0.06 0.22± 0.03 † 0.6 * 0.6
9(10)-EpODE 0.88± 0.11 2.0± 0.7 2.02± 0.70 1.30± 0.22 0.1 0.32 0.1 0.3
14(15)-EpETrE 9.49± 0.70 2.09± 0.19 13.4± 1.44 2.32± 0.26 ‡ ‡ * 0.4
11(12)-EpETrE 21.8± 1.5 5.57± 0.76 28.4± 3.1 5.39± 0.54 ‡ ‡ 0.07 0.8
8(9)-EpETrE 11.5± 0.88 2.72± 0.58 14.9± 1.6 2.64± 0.26 ‡ ‡ 0.07 0.9
17(18)-EpETE — 4.49± 0.67 — 7.15± 0.92 — — — *
14(15)-EpETE 0.07± 0.02 1.17± 0.12 0.15± 0.08 1.84± 0.24 ‡ ‡ 0.4 *
11(12)-EpETE 0.03± 0.00 2.12± 0.27 0.06± 0.02 3.11± 0.35 ‡ ‡ 0.2 *
19(20)-EpDoPE 2.72± 0.23 81.6± 8.9 2.93± 0.38 137± 17 ‡ ‡ 0.6 *
16(17)-EpDoPE 1.07± 0.19 24.8± 2.33 1.04± 0.16 36.0± 3.7 ‡ ‡ 0.9 *
13-HpODE screen 0.01± 0.00 0.07± 0.04 0.03± 0.01 0.03± 0.01 0.1 1 0.3 0.3
9-HpODE screen 0.09± 0.02 0.73± 0.44 0.21± 0.13 0.25± 0.06 0.2 0.8 0.3 0.3
15-HpETE screen 0.03± 0.01 0.03± 0.02 0.06± 0.02 0.01± 0.00 0.8 0.09 0.3 0.4
12-HpETE screen 0.08± 0.03 0.01± 0.00 0.12± 0.07 0.04± 0.02 * 0.2 0.6 0.2
Abbreviations: CYP, cytochrome P450 superfamily; DHA, docosahexaenoic acid; LOX, lipoxygenase pathway; sEH, soluble epoxide hydrolase. LOX: 5-HEPE,
5-hydroxy-6E,8Z,11Z,14Z,17Z-eicosapentaenoic acid; 12-HEPE, 12-hydroxy-5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid; 5-HETE, 5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic
acid; 9-HETE, 9-hydroxy-5E,7Z,11Z,14Z-eicosatetraenoic acid; 12-HETE, 12-hydroxy-5E,8Z,10Z,14Z-eicosatetraenoic acid; 15-HEPE, 15-hydroxy-5Z,8Z,11Z,13E,17Z-
eicosapentaenoic acid; 15-HETE, 15-hydroxy-15-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid; 17-HDoHE, 17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid.
CYP: 8(9)-EpETrE, 8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic acid; 11(12)-EpETrE, 11(12)-epoxy-5Z,8Z,14Z-eicosatrienoic acid; 14(15)-EpETrE, 14(15)-epoxy-5Z,8Z,
11Z-eicosatrienoic acid; 16(17)-EpDPE, 16(17)-epoxy-4Z,7Z,10Z,13Z,19Z-docosapentaenoic acid; 17(18)-EpETE, 17(18)-epoxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid.
sEH: 5,6-DiHETrE, 5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid; 8,9-DiHETrE, 8,9-dihydroxy-5Z,11Z,14Z-eicosatrienoic acid; 11,12-DiHETrE-1,12-dihydroxy-5Z,8Z,
14Z-eicosatrienoic acid; 14,15-DiHETE, 14,15-dihydroxy-5Z,8Z,11Z,17Z-eicosatetraenoic acid; 14,15-DiHETrE, 14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoic acid;
17,18-DiHETE, 17,18-dihydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid; 19,20-DiHDPA, 19,20-dihydroxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid. Values are
mean± s.d. of nine samples from each group at each time point (values expressed as nM). Differences between diet groups and between time within the same
diet groups were compared by Mann–Whitney U-test. Significant differences in means: *Po0.05, †Po0.01 and ‡Po0.001.
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16:1n7/16:0) and of lipogenesis (that is, 16:0/18:2n6)38 in the liver
were lower in the DHA group compared with the control diet-fed
mice after 118 days of feeding. Such indices of steroyl-coenzyme A
desaturase activity have previously been found to be elevated in
individuals with abnormally high liver fatty acid synthesis39 and at
risk for nonalcoholic fatty liver disease40 as well as insulin
resistance.41 Moreover, these results are consistent with previous
reports regarding the suppression of lipogenesis and steroyl-
coenzyme A desaturase activity by n-3 feeding in mice,42 and may
account for the reduced fat accumulation in the DHA group
(Supplementary Table 5).
A considerable number of AA-derived oxylipins were lower in
plasma, whereas those derived from n-3 PUFA were higher in mice
fed the DHA diet. These findings are consistent with previous
reports43 as numerous oxylipins showed changes paralleling shifts
in tissue fatty acid composition (that is, increasing n-3 PUFA- and
decreasing n-6 PUFA-derived oxylipins with DHA feeding) and
large increases in eicosapentaenoic acid-derived metabolites are
consistent with significant DHA retroconversion.44 Interestingly, of
the numerous linoleate and α-linoleate-derived oxylipins mea-
sured, only 13-hydroxyoctadecadienoic acid was significantly
changed by DHA feeding, with an approximately twofold increase
after both 62 and 118 days. The implications of this change are
unknown. The two- to six-fold reduction in classic 5-lipoxygenase-
dependent pro-inflammatory mediators suggests a significant
reduction in inflammatory tone, whereas the insignificant changes
in PGF2α, 9-HETE and the measured fatty acid hydroperoxides of
linoleate (HpODEs) and arachidonate (HpETEs) indicate that the
different diets were not associated with significant differences in
systemic oxidative stress.
Regarding plasma EC and EC-like compounds, the mice fed the
DHA diet had reduced AEA and 2-AG but increased putative-
cannabinoid receptor agonist DHEA. Reduction of the n-6/n-3
PUFA ratio and subsequent lowering of 2-AG has been observed
in overweight and obese subjects given krill oil.24 An increase of
circulating AEA and 2-AG has been reported in mice given dietary
linoleic acid, leading to the development of diet-induced
obesity.45 The n-3 PUFA-derived EC-like ligands have previously
showed binding potential to cannabinoid receptors, with a greater
affinity toward CB1 than CB2.46,47 Although DHEA showed a lower
affinity toward cannabinoid receptors than AEA, competition
between these ligands still occurs, and the presence of DHEA may
lower the likelihood of cannabinoid receptor activation. The classic
CB2 receptor ligand, AEA, increases in humans with type 2 diabetes28
and regulates food intake in food-deprived mice, with peripheral AEA
administration promoting hyperphagia in partially satiated mice.48
With the exception of palmatoylethanolamide, DHA feeding
reduced the levels of all other measured acylethanolamides.
Palmatoylethanolamide is an EC-like compound with peroxisome
proliferator-activating receptor α-dependent anti-inflammatory
effects.49 DHA feeding was generally associated with a decline
in monoacylglycerides, and inverse correlations between this
compound class and adiposity have been previously reported.28
In addition to the observed changes in circulating ECS ligands,
expression of ECS-associated genes was also altered. The increase
in mRNA levels of CB1, CB2, NAPE-PLD, DAGL-α, DAGL-β and FAAH
in quadriceps of mice suggest an ever-increasing ability to turn
over the ECS after 62 and 118 days of dietary DHA enrichment.
Epididymal fat pads shared a similar response to muscle in mice
fed the DHA diet as CB2 and NAPE-PLD were higher after 62 days,
whereas CB2, NAPE-PLD and FAAH were higher after 118 days. As
the DHA-derived DHEA is a weaker cannabinoid receptor ligand
than AEA,50 an increase in these ECS-related mRNA levels could be
a compensatory response.
The DHA-fed mice were found to have a lower potential for ECS
activation, coinciding with an increase in adiponectin mRNA
expression. The reduced expression of mitogen-activated protein
kinase enzymes, p42/p44, p38 and Jun N-terminal kinase mRNA,
and higher levels of adenylyl cyclase identified elsewhere,4,33 are
consistent with a reduction in ECS activation. Epididymal fat pad
adiponectin mRNA expression was higher at both time points in
mice fed the DHA diet. Adiponectin is an adipose-specific peptide
hormone reported to reduce the expression of enzymes involved
in lipogenesis and regulate glucose levels in humans51 and mice.52
CB1 activation by natural and synthetic ligands downregulates the
expression and release of adiponectin.14,53 Therefore, a decrease
in CB1 agonist tone leading to an increase in adiponectin
expression is consistent with the fat mass reduction observed in
the DHA-fed mice.
AMPK mRNA was found to be higher in mice fed the DHA diet
in both quadriceps and epididymal fat pads. AMPK is a known
regulator of cellular energy metabolism, in which activation has
been shown to inhibit lipogenesis.54 Although AMPK activation
was not measured, elevated levels of mRNA indicate a lowered
potential of lipid accumulation. Previously, AMPK activation has
been found to improve glucose tolerance.55 Long-term adminis-
tration of 5-aminoimidazole-4-carboxamide ribonucleoside, a drug
that activates AMPK, to insulin-resistant Zucker rats was shown to
improve glucose tolerance and reduce lipid accumulation. Others
have shown that CB1 antagonism promoted an increase whereas
activation led to a decrease in AMPK mRNA levels.12 Liver samples
treated with Δ-9-tetrahydrocannabinol resulted in a decrease in
AMPK activity.56 The results described in our study indicate that
cannabinoid receptors are involved in metabolic processes related
to glycolytic and oxidative flux for energy uptake and utilization in
skeletal muscle. The impact on the metabolic regulatory
machinery such as AMPK demonstrates a role of the ECS in fatty
acid oxidation and glucose flux in skeletal muscle.
As shown in Figure 1, CB2 was found to be higher in epididymal
fat pad of mice fed the DHA diet after 62 days. CB2 has been
previously found to be involved in whole body glucose
tolerance.57 When CB2 activation via specific agonists in rodents
were concurrently treated with CB1 antagonism, non-insulin-
stimulated glucose clearance was vastly improved. However,
when CB2 was antagonized or CB1-specific agonists were
administered, basal glucose clearance was impaired compared
with the untreated cage mate. This study depicts CB1 and CB2 as
having opposing effects with regard to glucose utilization.57 In the
current study, higher levels of GLUT1 mRNA but lower levels of
GLUT4, insulin receptor and Akt-1 in epididymal fat pads imply
that DHA improved aspects of basal glucose uptake. Higher levels
of GLUT1, GLUT4, Akt-1, insulin receptor and insulin receptor
substrate-1 in quadriceps suggest that the potential for both
insulin-stimulated and basal glucose uptake are improved with
DHA feeding to mice. Despite possessing a lower affinity, DHEA
can also bind to both cannabinoid receptors.47 Thus, higher levels
of DHEA availability can result in competition with other ECs
sharing affinity for the same receptors, possibly resulting in lower
CB1 or CB2 activation. In addition, evidence of distinct down-
stream events after treatment with different ECs have been
observed by our group such as greater uptake of glucose in
proliferating and differentiated myoblast with DHEA compared
with AEA or 2-AG.20 These findings could indicate a tissue-specific
difference in how DHA may modulate the ECS that can ultimately
influence metabolism of glucose.
While acknowledging the limitations of quantitative real-time
PCR data, we believe that demonstrating mRNA measurements at
two time points supported with DXA measurements of body fat is
suggestive of an important relationship between dietary DHA and
the ECS. However, this investigation would benefit from protein
measurements of the genes examined. Future studies that include
protein expression of AMPK, p42/44, p38 and Jun N-terminal
kinase to validate downstream effectors of ECS activation will
advance the understanding of dietary DHA.
Based on the findings of this investigation, DHA feeding to
C57BL/6J mice led to compensatory increases of ECS-related
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mRNA levels and did not result in cannabinoid receptor activation.
Mice fed the DHA diet were also found to have significantly less
epididymal fat pad mass compared with control fed mice.
Coupled with the increased mRNA levels of adiponectin and
AMPK in epididymal fat pads, these findings suggest that a
decrease in ECS activation can lead to an increase in glucose
clearance and lipolysis in DHA-fed mice. It is likely that the
increase in DHA-derived and decrease in AA-derived EC levels in
mice fed the DHA diet are contributing factors for the results
observed (Figure 2). Thus, the current investigation revealed that
DHA can mediate ECS gene expression and positively influence
the metabolism of systemic macromolecules.
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